Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

Aramchol (C20-FABAC, Icomidocholic acid) is a fatty acid-bile acid conjugate that reduces liver fat content and is a inhibitor of stearoyl CoA desaturase 1 (SCD1) and a cholesterol solubilizer. It can be used in research on fatty liver disease, blocking fibrosis by targeting hepatic stellate cells in liver injury, non-alcoholic steatohepatitis (NASH) and nonalcoholic fatty […]

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

RP-6685 is a potent, selective, and orally active inhibitor of DNA polymerase theta (Polθ). RP-6685 exhibits antitumor efficacy in animal models.

SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels.